Lifecore Biomedical
LFCR
96 hedge funds and large institutions have $263M invested in Lifecore Biomedical in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 33 increasing their positions, 37 reducing their positions, and 18 closing their positions.
9% less capital invested
Capital invested by funds: $289M → $263M (-$26M)
11% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 37
12% less funds holding
Funds holding: 109 → 96 (-13)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
72% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$12.3M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
+$3.35M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$2.83M |
| 4 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$1.71M |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KG
Killen Group
Berwyn,
Pennsylvania
|
-$3.77M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$2.51M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$1.92M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.89M |
| 5 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
-$939K |
LFCR Hedge Fund Activity: Q1 2016 in Review
96 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2016, worth a combined $263M — down 9% from $289M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LFCR and 5 opened new positions — a net loss of 13 holders — while 37 trimmed existing stakes and 33 added.
The largest buyer was Franklin Resources, adding an estimated $12.3M. The largest seller was Killen Group, cutting an estimated $3.77M.
- 96 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2016, down from 109 in Q4 2015.
- Funds reported $263M of Lifecore Biomedical stock for Q1 2016, down 9% quarter-over-quarter.
- 5 funds opened new Lifecore Biomedical positions in Q1 2016 and 18 closed out, a net change of -13 holders.
- The largest Lifecore Biomedical buyer in Q1 2016 was Franklin Resources, an estimated $12.3M added.
- The largest Lifecore Biomedical seller in Q1 2016 was Killen Group, an estimated $3.77M sold.
Based on aggregated 13F filings for Q1 2016.